^
    Back
    Association details:
    Biomarker:CCR4 positive
    Cancer:Lymphoma
    Drug:Poteligeo (mogamulizumab-kpkc) (CCR4 receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL

    Excerpt:
    ...Histologically confirmed diagnosis of a CCR4-positive ATL and...
    Trial ID:
    NCT00355472
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ICML 2023
    Title:

    A PHASE 2 TRIAL OF CHOP WITH ANTI-CCR4 ANTIBODY MOGAMULIZUMAB FOR ELDERLY PATIENTS WITH CCR4-POSITIVE ADULT T-CELL LEUKEMIA/LYMPHOMA

    Published date:
    06/09/2023
    Excerpt:
    This study demonstrated that Moga-CHOP-14 significantly improved PFS in elderly patients with aggressive CCR4-positive ATL who were ineligible for allo-HSCT.
    Secondary therapy:
    CHOP
    DOI:
    10.1002/hon.3163_125